A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC

Prior treatment

• Major surgery (other than aspiration biopsy) within 28 days prior to the first dose of study drug or significant trauma,or required to undergo scheduled surgery during the trial.
• Use of immunomodulatory drugs within 14 days before the first use of study drug,Including but not limited to thymopeptide, interleukins, interferon, etc.
• Patients with active infection requiring intravenous anti-infective therapy within 2 weeks prior to the first dose of study drug.

Other illness

• serious cardiac and cerebrovascular disorder.
• History of immunodeficiency including HIV antibody test positive.
• patients with active hepatitis B or C.
• The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.

Other

• Diagnosed with Mixed neuroendocrine-non endocrine neoplasm (MiNENs).
• Women during pregnancy or lactation.

• Agrees to follow the investigational treatment protocol, visit schedule and laboratory test, comply with other requirements of the protocol, voluntarily enroll, and sign a written informed consent.
• Age ≥ 18 years (inclusive) at the time of signing informed consent.
• The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1.
• expected survival time of at least 12 weeks.
• According to RECIST 1.1, participants were required to have at least one measurable lesion.
• Male of childbearing potential and Females of childbearing age are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug.